ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

September 06, 2007 10:08 ET

ART Appoints DiCamillo to Senior-Level Position of Global Sales & Marketing VP for Preclinical Imaging with Mandate to Implement Direct Commercialisation Strategy for its Optix Imaging System

25-year industry veteran with track record in top-level sales and marketing positions to take on responsibility for direct distribution of ART's Optix® imaging system in North America and Europe, as part of several key additions to the ART commercialization team.

MONTREAL, CANADA--(Marketwire - Sept. 6, 2007) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today announced that Mr. Dino DiCamillo has joined the Company as an executive officer and Vice President, Global Sales & Marketing, Preclinical Imaging (subject to regulatory approval). With over 20 years of top-level sales, marketing, and customer support experience behind him, Mr. DiCamillo will be leading the overall worldwide preclinical sales and marketing efforts for ART. His primary responsibility will be to develop a strong results-oriented sales team and grow the market share for ART's preclinical products by building direct distribution channels for the Optix® optical imaging system in North America and Europe. Prior to joining ART, Mr. DiCamillo was President of the proteomic technology division of AlfaWassermann, and held executive management positions at Invitrogen Corp., Dynal Biotech LLC. and Applied Biosystems Inc., where he distinguished himself as a top performer in sales revenue generation and in customer support and services.

"We are very pleased to have Dino DiCamillo join the ART team to lead and implement the direct commercialization strategy for our Optix fluorescent molecular imaging system. Dino has a superb track record of growing the top line at many companies in the preclinical instrument market. Dino's appointment is a critical step in the implementation of our new commercial strategy of distributing our preclinical molecular imaging solutions directly to customers in North America and Europe and I view his joining ART as a major sign of confidence in our technology and our products," said Mr. Sebastien Gignac, ART's President and CEO.

Mr. DiCamillo commented: "I am very excited to take on this opportunity to lead ART's sales and marketing effort in preclinical imaging. ART's technological leadership in optical molecular imaging is second to none and I see optical imaging as being at the forefront of the rapid expansion and integration of molecular imaging into drug research and development. I look forward to continuing to advance ART's leading molecular imaging platform with customers and partners in this fast-growth market segment."

Following a short transition during which ART assumed responsibility for distributing the Optix system directly in North America, the Company is now moving, under Mr. DiCamillo's leadership, to expand its direct distribution channels for its Optix system to include Europe -as well. The Company is still in discussions with GE Healthcare for the distribution of the Optix product in Asia, and more specifically in Japan - where ART's Fenestra® contrast agent product is already distributed by GE Japan.

Mr. Pierre Couture who, until recently was the top sales and marketing executive responsible for managing the relationship with GE Healthcare will now be focusing on commercial partnerships and collaborations and work closely with Mr. DiCamillo in supporting the commercialization effort for the Company's preclinical imaging products.

Dr. Patricia Bresnahan has also recently joined the Company as Marketing Director, Preclinical Imaging. In this capacity, she is responsible for the roll out of the Company's preclinical marketing strategy, including product definition and customer feedback, and will report to Mr. DiCamillo. Dr. Bresnahan is also responsible for a sales territory in California (the San Francisco Bay area). Before joining ART, Dr. Bresnahan was Marketing Manager, Asia Pacific region, for GE Healthcare / Amersham Biosciences. In addition to her marketing experience, she also has over 12 years in research project leadership and holds a doctorate degree in cell biology from Oregon Health Sciences University and held two post-doctoral positions at the University of California San Francisco.

In a related announcement, ART appointed Mr. Mark J. Sutherland to its Business Advisory Council. Mr. Sutherland, a seasoned life sciences sales and marketing executive, brings a wealth of experience from his 25 years in business development, strategic marketing and product management. Presently Chief Business Officer at FlashPoint Technology where he is accountable for all commercial activities, he has held senior positions at GE Healthcare, Amersham Biosciences, Molecular Dynamics and Applied Biosystems Inc.

About Dino DiCamillo

Prior to joining ART, Dino DiCamillo spent the last 25 years in the research, discovery, and preclinical market arena. He has held various sales, marketing, and business leadership roles as President of Alfa Wassermann Proteomic Technology Inc., Vice President. of Environmental Diagnostics at Invitrogen Corporation, President of Dynal Biotech LLC, and Senior Field Manager at Applied Biosystems Inc. where he was an integral part of the commercial team that grew the business from under US$40 million to over US$1.7 billion in annual revenue over a period of 13 years. Mr. DiCamillo was also a Sales Engineer at Bio-Rad Laboratories. Mr. DiCamillo holds an EMBA from Temple University and a B.S. in Biology from Lake Superior State University. Dino DiCamillo and his spouse Martha, and their two children, Bianca and Alexis, reside in the greater Philadelphia area.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contact Information